| Registry | NCT06200220 |
|---|---|
| Status | Unknown |
| Study type | Observational |
| Enrollment | 45 (Estimated) |
| Sponsor | Poitiers University Hospital (Other) |
| Conditions | Waldenstrom's Macroglobulinaemia Refractory |
| Interventions | Venetoclax (Drug) |
| Dates | start 2023-12-28, primary completion 2023-12-28, completion 2025-12-01 (estimated), first posted 2024-01-10, last updated 2024-01-10 |
| Locations | 1 site in France |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Waldenstrom's Macroglobulinaemia Refractory All trials of Venetoclax
Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Waldenstrom's macroglobulinemia * Treatment with Venetoclax * Non opposition Exclusion Criteria: none
| Facility | City | Country | Status |
|---|---|---|---|
| CHU Poitiers | Poitiers | France | Recruiting |